ClinicalTrials.gg
CompletedNCT02157298Updated May 11, 2016Results posted

Phase IV Study With a 36-week Extension Period to Evaluate the Efficacy and Safety of Dapagliflozin Therapy When Added to the Therapy of Japanese Patients With Type 2 Diabetes With Inadequate Glycemic Control on Insulin.

A Phase 4 interventional study of Dapagliflozin 5 mg and Placebo tablet in Type 2 Diabetes Mellitus, sponsored by AstraZeneca. Completed at 14 sites in Japan. Open to participants aged 20 Years to 130 Years. Per ClinicalTrials.gov, last updated 2016-05-11.

Sponsored by AstraZeneca · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
266
Allocation
Randomized
Ages
20 Years to 130 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 180 studies testing dapagliflozin in Diabetes Mellitus, Type 2 — 15 open to participants now, 19 under way, 5 of them phase 3. dapagliflozin · Diabetes Mellitus, Type 2.

Enrollment
46th of 180
266 · median 82
Started
2014
with 8 others
Phase 4
77 of 180
7 open now
Registered
48th of 180
by date
Lead sponsor
72 of 180
AstraZeneca

Among the 180 studies testing dapagliflozin in Diabetes Mellitus, Type 2, this one is the 46th largest by enrollment, is one of 9 that started in 2014, is one of 77 in phase 4, and was the 48th registered.

Diabetes Mellitus, Type 2

10,396 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,415 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

15 of the 180 studies testing dapagliflozin in Diabetes Mellitus, Type 2 are open now, in 12 countries. Recruiting first, the newest first:

10 more — sign in →

By country, each count listing its studies:

All 15 open studies →

About dapagliflozin

dapagliflozin: first FDA approval 2014 (FARXIGA), first EMA approval 2012. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 881 Diabetes Mellitus, Type 2 studies recruiting now, 375 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.

This study: 20 Years to 130 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 180 studies testing dapagliflozin in Diabetes Mellitus, Type 2, or all of them as a file.
02

Study summary

Japanese male and female patients with Type 2 Diabetes and aged ≥ 20 years old, with inadequate glycemic control on insulin defined as Haemoglobin A1c ≥ 7.2% and \< 11% will be enrolled into the wash-out phase or directly into the lead-in phase depending on whether the patient has been receiving an Oral antidiabetic drug (including Glucagon-Like Peptide-1 agonists and excluding Thiazolidinedions) other than a Dipeptidyl Peptidase-4 inhibitor as part of the baseline treatment. Additional treatment with a concomitant Dipeptidyl Peptidase-4 inhibitor is allowed. And around 180 eligible patients in total will be randomized into the study with a 2:1 randomization scheme (i.e.120 patients into the dapagliflozin treatment group and 60 patients into the placebo treatment group. All subjects who completed a 16 weeks double-blind treatment period will shift to a 36 weeks open extension treatment period.

03

Conditions studied

  • Type 2 Diabetes Mellitus

Keywords

  • Japanese patients with type 2 diabetes with inadequate glycemic control on insulin
04

Who can participate

Ages eligible
20 Years to 130 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Provision of prior to any study specific procedures
  • Diagnosis of Type 2 Diabetes according the criteria specified by the Japan Diabetes Society
  • Japanese Men or women age ≥ 20 years at time of consenting.
  • Stable (unless adjustment is required based on Fasting Plasma Glucose values) dose insulin* mono-therapy with the mean insulin [up to two types of insulin within authorized indication in Japan] dose of ≥ 0.2 IU/kg/day AND ≥ 15 IU/body/day over the past 8 weeks prior to enrolment.
  • ≥ 7.2% and \< 11% from the blood samples collected at Visit 1 (enrolment) and Visit 3, observed from the central laboratory

Exclusion criteria

Exclusion Criteria:

  • Diagnosis of Type 1 diabetes mellitus, known diagnosis of Maturity Onset Diabetes of the Young, secondary diabetes mellitus or diabetes insipidus
  • History of diabetic ketoacidosis.
  • Thyroid-stimulating hormone and free T4 values outside normal range, observed from the central laboratory; an abnormal Thyroid-stimulating hormone value needs to be followed up with a free T4 test. Patients with abnormal free T4 values will be excluded at Visit 1
  • Fasting Plasma Glucose >240 mg/dL (twice in a row) despite the permitted dose adjustment of insulin therapy during and lead-in period.
  • Recent cardiovascular events in a patient.
  • \<45 mL/min/1.73 m2 at Visit 3, observed from the central laboratory.
  • History of unstable or rapidly progressing renal disease.
  • History of unexplained microscopic or gross hematuria, or microscopic hematuria at Visit 1, confirmed by a follow-up sample at next scheduled visit, where according to the investigator a satisfactory evaluation of hematuria has not been conducted.
  • Severe hepatic insufficiency and/or significant abnormal liver function defined as (AST) >3x (ULN) and/or alanine aminotransferase (ALT) >3x ULN, observed from the central laboratory at Visit 1.
  • Total >2.0 mg/dL (34.2 μmol/L), observed from the central laboratory at Visit 1.
  • Positive serologic evidence of current infectious liver disease including Hepatitis A viral antibody IgM, surface antigen and virus antibody, observed from the central laboratory.
  • \<10 g/dL (\<100 g/L) or 6.2 mmol/L for men; haemoglobin \<9.0 g/dL (\<90 g/L) or 5.9 mmol/L for women, observed from the central laboratory at Visit 1.
  • History of chronic haemolytic anaemia or haemoglobinopathies (for example, sickle cell anaemia, thalassemia, sideroblastic anaemia). Mild haemolysis due to artificial heart valves or due to sickle cell trait is not an exclusion criterion except when haemoglobin levels are too low (as defined in haemoglobin criteria above).
  • History of within the last 5 years prior to enrolment, excluding successful treatment of basal or squamous cell skin cancer.
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
266 participants (actual)

Study arms

  • Experimental
    dapagliflozin 5mg

    dapagliflozin tablet 5mg

    Drug: Dapagliflozin 5 mg

  • Placebo comparator
    Placebo

    dapagliflozin tablet 5mg placebo

    Drug: Placebo tablet

Interventions

  • Dapagliflozin, a blood glucose lowering drug. Oral dose

  • DrugPlacebo tablet

    Placebo tablet. Oral dose

06

What researchers measure

Primary outcomes

  1. Adjusted Mean Change in HbA1c Levels

    Mean change in HbA1c levels from baseline to Week 16 between dapagliflozin 5 mg versus placebo

    Time frame: Baseline to Week 16

Secondary outcomes

  1. Fasting Plasma Glucose

    Mean change in fasting plasma glucose from baseline to Week 16 between dapagliflozin 5 mg versus placebo

    Time frame: Baseline to Week 16

  2. Total Body Weight

    Mean change in total body weight from baseline to Week 16 between dapagliflozin 5 mg versus placebo

    Time frame: Baseline to Week 16

  3. Total Mean Daily Insulin Dose

    Mean change in calculated mean daily insulin dose from baseline to Week 16 between dapagliflozin 5 mg versus placebo

    Time frame: Baseline to Week 16

  4. Proportion of Participants With Mean Daily Insulin Dose Reduction of Greater Than or Equal 10%

    Proportion of participants with mean daily insulin dose reduction greater than or equal 10% from baseline to week 16 (LOCF) between dapagliflozin 5 mg versus placebo

    Time frame: Baseline to Week 16

07

Results

Posted Mar 17, 2016
Limitations and caveats
For HbA1c, FPG and TBW: excluding data after insulin up-titration and for Mean Daily Insulin Dose: including data after insulin up-titration were used. For participants who did not complete week 16 last observation carried forward (LOCF) was used.

Participant flow

First participant enrolled: 06-Jun-2014; Last participant last visit of ST period: 02-Feb-2015; 266 participants were enrolled in 20 Japanese centers. 183 Japanese men or women aged \>=20 years with inadequate glycemic control (HbA1c levels of \>=7.2% to \<11.0%) with diet, exercise and on stable dose of insulin +/- DPP-4 inhibitor were treated.

Participant flow — Overall Study
MilestoneDapagliflozinPlacebo
Started12360
Completed11958
Not completed42
Withdrew: Adverse event10
Withdrew: Subject no longer meets study criteria12
Withdrew: Poor/non-compliance10
Withdrew: Withdrawal by subject10

Outcome measures

PrimaryAdjusted Mean Change in HbA1c Levels

Mean change in HbA1c levels from baseline to Week 16 between dapagliflozin 5 mg versus placebo

Time frame:
Baseline to Week 16
Reported as:
Least squares mean · percentage of hemoglobin glycosylated
Adjusted Mean Change in HbA1c Levels
percentage of hemoglobin glycosylatedDapagliflozinPlacebo
Adjusted Mean Change in HbA1c Levels-0.55 (-0.67 to -0.42)0.05 (-0.13 to 0.23)
Statistical analysis
  • Dapagliflozin vs Placebo · Mixed Models Analysis · p = <0.0001 (Significant at alpha=0.05 (two-sided). Primary and key secondary endpoints are tested following a hierarchical closed testing procedure) · Mean difference (final values): -0.60 · 95% CI -0.81 to -0.39with fixed categorical effects of treatment, week, DPP-4, baseline eGFR, treatment-by-week interaction, continuous fixed covariate of baseline value.
SecondaryFasting Plasma Glucose

Mean change in fasting plasma glucose from baseline to Week 16 between dapagliflozin 5 mg versus placebo

Time frame:
Baseline to Week 16
Reported as:
Least squares mean · mg/dL
Fasting Plasma Glucose
mg/dLDapagliflozinPlacebo
Fasting Plasma Glucose-21.7 (-28.3 to -15.1)1.0 (-8.4 to 10.3)
Statistical analysis
  • Dapagliflozin vs Placebo · Mixed Models Analysis · p = <0.0001 (Significant at alpha=0.05 (two-sided). Primary and key secondary endpoints are tested following a hierarchical closed testing procedure) · Mean difference (final values): -22.7 · 95% CI -33.2 to -12.2with fixed categorical effects of treatment, week, DPP-4, baseline eGFR, treatment-by-week interaction, continuous fixed covariate of baseline value.
SecondaryTotal Body Weight

Mean change in total body weight from baseline to Week 16 between dapagliflozin 5 mg versus placebo

Time frame:
Baseline to Week 16
Reported as:
Least squares mean · kg
Total Body Weight
kgDapagliflozinPlacebo
Total Body Weight-0.6 (-0.9 to -0.2)0.7 (0.2 to 1.1)
Statistical analysis
  • Dapagliflozin vs Placebo · Mixed Models Analysis · p = <0.0001 (Significant at alpha=0.05 (two-sided). Primary and key secondary endpoints are tested following a hierarchical closed testing procedure) · Mean difference (final values): -1.2 · 95% CI -1.7 to -0.7with fixed categorical effects of treatment, week, DPP-4, baseline eGFR, treatment-by-week interaction, continuous fixed covariate of baseline value.
SecondaryTotal Mean Daily Insulin Dose

Mean change in calculated mean daily insulin dose from baseline to Week 16 between dapagliflozin 5 mg versus placebo

Time frame:
Baseline to Week 16
Reported as:
Least squares mean · IU/Day
Total Mean Daily Insulin Dose
IU/DayDapagliflozinPlacebo
Total Mean Daily Insulin Dose-0.74 (-1.21 to -0.27)-0.02 (-0.68 to 0.64)
Statistical analysis
  • Dapagliflozin vs Placebo · Mixed Models Analysis · p = 0.0743 (Significant at alpha=0.05 (two-sided). Primary and key secondary endpoints are tested following a hierarchical closed testing procedure) · Mean difference (final values): -0.72 · 95% CI -1.51 to 0.07with fixed categorical effects of treatment, week, DPP-4, baseline eGFR, treatment-by-week interaction, continuous fixed covariate of baseline value.
SecondaryProportion of Participants With Mean Daily Insulin Dose Reduction of Greater Than or Equal 10%

Proportion of participants with mean daily insulin dose reduction greater than or equal 10% from baseline to week 16 (LOCF) between dapagliflozin 5 mg versus placebo

Time frame:
Baseline to Week 16
Reported as:
Least squares mean · percentage of participants
Proportion of Participants With Mean Daily Insulin Dose Reduction of Greater Than or Equal 10%
percentage of participantsDapagliflozinPlacebo
Proportion of Participants With Mean Daily Insulin Dose Reduction of Greater Than or Equal 10%8.2 (3.3 to 13.1)4.9 (-0.7 to 10.4)
Statistical analysis
  • Dapagliflozin vs Placebo · Regression, Logistic · p = 0.3727 (Significant at alpha=0.05 (two-sided). Primary and key secondary endpoints are tested following a hierarchical closed testing procedure) · Risk difference (rd): 3.4 · 95% CI -4.0 to 10.7Based on methodology of Zhang, Tsiatis \& Davidian and Tsitatis, Davidian, Zhang \& Lu, with adjustment with adjustment for baseline value and DPP-4

Adverse events

Collected over Non-serious/serious adverse events on or after the first date of double-blind treatment and on or prior to the last day plus 4/30 days or up to follow-up visit if earlier, or up to and excluding the start date of open-label extension period if earlier.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Dapagliflozin—3/123 (2.4%)24/123 (19.5%)
Placebo—0/60 (0%)10/60 (16.7%)
Most frequent serious events
Most frequent serious events
EventDapagliflozinPlacebo
CholelithiasisHepatobiliary disorders1/1230/60
Hand fractureInjury, poisoning and procedural complications1/1230/60
OsteochondrosisMusculoskeletal and connective tissue disorders1/1230/60
Most frequent other events
Most frequent other events
EventDapagliflozinPlacebo
NasopharyngitisInfections and infestations13/1237/60
PollakiuriaRenal and urinary disorders11/1233/60
ConstipationGastrointestinal disorders3/1233/60

Baseline characteristics

The Full Analysis Set defined as all randomized participants (as randomized) who received at least one dose of double-blind study medication, who have a non-missing baseline value and at least one post-baseline efficacy value for at least one efficacy variable during the short-term double-blind treatment period.

Age, Continuous
Age, Continuous(years)DapagliflozinPlaceboTotal
Mean58.3 ± 9.8357.6 ± 9.8658.0 ± 9.82
Age, Customized
Age, Customized(participants)DapagliflozinPlaceboTotal
<=65 years8443127
Between 65 and 75 years371653
>=75 years112
Sex: Female, Male
Sex: Female, Male(Participants)DapagliflozinPlaceboTotal
Female332053
Male8940129
Region of Enrollment
Region of Enrollment(participants)DapagliflozinPlaceboTotal
Japan12260182
Body Weight
Body Weight(kg)DapagliflozinPlaceboTotal
Mean73.90 ± 15.66371.89 ± 13.43073.24 ± 14.956
Body Mass Index
Body Mass Index(kg/m^2)DapagliflozinPlaceboTotal
Mean26.89 ± 4.93026.12 ± 3.48526.64 ± 4.510
Waist Circumference
Waist Circumference(cm)DapagliflozinPlaceboTotal
Mean93.2 ± 11.8392.3 ± 9.0092.9 ± 10.96
HbA1c
HbA1c(percent of hemoglobin glycosylated)DapagliflozinPlaceboTotal
Mean8.26 ± 0.7928.52 ± 0.9378.34 ± 0.849

3 further baseline measures are reported on the registry.

08

Study locations

14 sites
  • Research Site
    Adachi-ku, Japan
  • Research Site
    Chitose-shi, Japan
  • Research Site
    Chiyoda-ku, Japan
  • Research Site
    Chuo-ku, Japan
  • Research Site
    Fukuoka-shi, Japan
  • Research Site
    Hirosaki-shi, Japan
  • Research Site
    Kamakura-shi, Japan
  • Research Site
    Koriyama-shi, Japan
  • Research Site
    Mitaka-shi, Japan
  • Research Site
    Oita-Shi, Japan
  • Research Site
    Osaka-shi, Japan
  • Research Site
    Sendai-shi, Japan
  • Research Site
    Shizuoka-shi, Japan
  • Research Site
    Yokohama-shi, Japan
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jun 2014, a primary completion of Feb 2015 and a completion of Nov 2015. It does not say whether these dates are actual or estimated.

Results were first posted in Mar 2016, 1 year 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 2, 2014
First posted
Jun 6, 2014
Start
Jun 2014
Primary completionActual
Feb 2015
CompletionActual
Nov 2015
Results first posted
Mar 17, 2016
Last update
May 11, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 11, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02157298
Lead sponsor
AstraZeneca
Responsible party
Sponsor
First posted
Jun 6, 2014
Start date
Jun 2014
Primary completion
Feb 2015
Completion
Nov 2015
Results posted
Mar 17, 2016
Last update
May 11, 2016

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Dapagliflozin

Start the discussion